OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II study
Geert D’Haens(Amsterdam University Medical Centers), William J. Sandborn(University of San Diego), S D Lee(University of Washington), Walter Reinisch(Medical University of Vienna), D I Park(Kangbuk Samsung Hospital), Dino Tarabar(Military Medical Academy), Fabio Cataldi(Pfizer (United States)), Anindita Banerjee(Pfizer (United States)), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Édouard Louis(Centre Hospitalier Universitaire de Liège), Xavier Hébuterne, Kenneth J. Gorelick, J Klaus(University Hospital Ulm), Maria Kłopocka(Nicolaus Copernicus University)
Cited by 6
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k